Corchorusoside B

Metabolite details

Identifier

HNHIWJNROSKAOI-UHFFFAOYSA-N

InChI Key

HNHIWJNROSKAOI-UHFFFAOYSA-N

IUPAC name

3-[11,14-dihydroxy-3-[4-hydroxy-6-methyl-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-uran-5-one

Preferred name

Corchorusoside B

INN name

—

Synonym

—

ChEBI

CHEBI:187073

Reactome pathways

• No Reactome pathways listed for this metabolite.

Observed in studies

• Bioaccumulation of therapeutic drugs by human gut bacteria: cross-feeding metabolite analysis (FIA-MS) (E.rectale;S.salivarius assays)
• Multi-Omics Analysis Reveals Disturbance of Nanosecond Pulsed Electric Field in the Serum Metabolic Spectrum and Gut Microbiota
• Diallyl disulfide (DADS) ameliorates intestinal Candida albicans infection by modulating the gut microbiota and metabolites and providing intestinal protection in mice
• Mechanism of interventional effect and targets of Zhuyu Pill in regulating and suppressing colitis and cholestasis
• Alterations in the gut microbiota and metabolomics of seafarers after a six-month sea voyage
• Disturbed Microbiota-Metabolites-Immune Interaction Network is Associated with Olfactory Dysfunction in Patients with Chronic Rhinosinusitis

Observed in differential profiles

• G4_Eubacterium_rectale_DMSO_30_vs_G3_Eubacterium_rectale_Duloxetine_47
• Control_vs_nsPEF_7_day
• G1_PBS_vs_G2_DSS
• Control_vs_ZYP_High_Dose
• Control_0d_vs_Treatment_180d
• Control_0d_vs_Treatment_180d
• Normal_vs_Abnormal